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Background/aim: Dyspnea is the subjective feeling of breathing discomfort, which is a significant problem for patients with heart and
respiratory disease and also an important determinant of exercise tolerance, quality of life, and mortality in various diseases. Most of the
scales are not enough to investigate the multidimensional effects of dyspnea; therefore, the Multidimensional Dyspnea Profile (MDP)
was developed and validated in many languages. This study aimed to translate and culturally adapt the MDP into Turkish and investigate
the psychometric properties of this adapted version in outpatients with respiratory disease.
Materials and methods: The MDP was translated and culturally adapted into Turkish following published guidelines. A total of 170
outpatients with respiratory disease were included to assess psychometric properties. The factorial structure was investigated using a
principal component analysis. Two situations were used in this study evaluating dyspnea in activity-related and resting conditions. We
formulated 17 hypotheses for each MDP domain (in total 68) to assess construct validity, and correlations were investigated between the
MDP and measures of body mass index, pulmonary function test, other dyspnea assessments, anxiety, depression, and health-related
quality of life. To investigate the test-retest reliability, the MDP was administered again after 1-h and 1 week.
Results: Internal consistency of the MDP was excellent (Cronbach’s alpha coefficients ranged from 0.89 to 0.93). The exploratory
factor analysis revealed 2 components explaining a 70% and 76% variance. Overall, 64 of the 68 predetermined hypotheses (94%) were
confirmed to test construct validity. The MDP showed excellent test-retest reliability for a 1-hperiod (intraclass correlation coefficient
values ranged from 0.98 to 0.99). However, test-retest reliability decreased moderate-to-high after 1 week (0.53–0.80).
Conclusion: The MDP was successfully translated and culturally adapted into Turkish and this version showed good psychometric
properties including the factorial structure, internal consistency, test-retest reliability, and construct validity to assess multidimensional
aspects of dyspnea.
Key words: Validity, reliability, dyspnea, multidimensional, Turkish, questionnaire

1. Introduction
Dyspnea is the subjective feeling of breathing discomfort,
which is a significant problem for patients with heart
and respiratory disease [1]. Dyspnea is also an important
determinant of exercise tolerance, quality of life, and
mortality in various diseases [2]. Recent research showed
that dyspnea is multidimensional, and different afferent
mechanisms can cause these dimensional variations [1–4].
Most of the common dyspnea measurements do not
adequately assess the complexity of dyspnea [5]. Scales such
as the Visual Analogue Scale (VAS) and the Modified Borg

Scale (MBS) are used to measure the severity of dyspnea
in unidimensional [6,7], or the Baseline/ Transitional
Dyspnea Index (BDI/TDI) and the modified Medical
Research Council (mMRC) Scale are used to assess the
effects of dyspnea on exercise capacity [8]. Unidimensional
scales are specific for a time point (current or recalled)
but do not evaluate the quality of unpleasantness,
breathing discomfort, or related emotional experiences.
Therefore, these scales are not enough to investigate the
multidimensional effects of dyspnea in individuals with
chronic pulmonary disease.
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The Dyspnea-12 score [9], Cancer Dyspnea Scale [10],
and the Multidimensional Dyspnea Profile (MDP) [4,5,11]
scales are multidimensional tools to assess dyspnea. The
Dyspnea-12 gives a sum score of total items and does not
assess feelings related to chest constriction, concentration,
anxiety, fear, or frustration. However, the MDP presents
sensory qualities, discomfort, and emotional responses to
the dyspnea experience [12]. The Cancer Dyspnea Scale
also gives a sum score, except for an anxiety score, and does
not provide enough information about other dimensions
of dyspnea [10]. The MDP can be used in clinical settings
[5] and experimental settings [4]. Users can define a
specified time frame or situation for the measure, which
can be changed based on the study design. It is easy to
understand the MDP, and the administration of MDP takes
approximately 2 min for most subjects and patients [12].
The MDP has an increasing use in international
studies and was previously validated and/or translated
into Dutch for Belgium and Netherlands; English for the
USA, Canada, UK, and Australia; French for Belgium,
Canada, and France; German for Germany, Swedish for
Sweden, and Portuguese for Brazil [12–18]. However, the
MDP does not have a Turkish validation. Therefore, this
study aimed to translate and culturally adapt the MDP into
Turkish investigating its psychometric properties including
the factorial structure, internal consistency, test-retest
reliability, and construct validity.
2. Materials and methods
2.1. Design and participants
Patients above the age of 18 years who presented to the
Department of Chest Diseases, Dokuz Eylül University
Hospital with documented physician-diagnosed chronic
respiratory disease, were recruited to this validation study
from July to December 2018. Patients with acute coronary
syndrome, advanced or metastatic cancer or the inability to
speak or understand Turkish were excluded.
Despite the lack of an internationally accepted
consensus about the minimum required sample size for
validation studies, it is generally recommended to include
2–20 participants per item [19]. Therefore, we determined
an a priori sample size of 110 patients, for 10 participants
per item.
The study was approved by the Noninvasive Research
Ethics Board of Dokuz Eylül University Hospital (approval
number: 2018/18-40 and date: 19.07.2018) and performed
following the ethical standards as laid down in the 1964
Declaration of Helsinki (as revised in Brazil 2013). All
the participants gave written informed consent before
participation in the study.
2.2. Study protocol
To examine the intrarater reliability, 1 physiotherapist
evaluated the same patient after 1-h and 1 week using

the MDP. To assess construct validity, the spirometry
results, the mMRC scale, VAS, MBS, Hospital Anxiety and
Depression Scale (HADS), and Nottingham Health Profile
(NHP) were used.
2.3. Translation and crosscultural adaptation
Permission for the Turkish validation study was obtained
by the Mapi Research Trust, Lyon, France. The MDP was
translated and culturally adapted following the published
guidelines [20]. First, English-to-Turkish translations were
done by 2 translators. After that, the expert committee
compared and discussed the 2 versions and made them 1
form for the Turkish-translated version. Two translators
performed back-translation of this from Turkish to
English. These translations were reviewed and compared
with the original scale by the expert committee. The backtranslation was sent to the Mapi Research Trust and it was
approved. Ten patients were tested using the prefinal MDP
version, and they did not suggest any change for clarity,
wording, terminology, or instructions. After this, the final
Turkish version of the MDP was ready to use.
2.4. Outcome measures
The demographic and clinical characteristics of the
patients were collected from the latest medical records
while crosschecking with patient interviews.
The MDP contains 11 items that evaluate Immediate
Perception (IP) (6 items; total score range is 0–60) and
Emotional Response (ER) (score range is 0–50) domains
of dyspnea [12]. The items are measured on a rating scale
of 0–10, with higher scores indicating greater intensity,
unpleasantness, or distress. Each item can be calculated
separately, or domain scores can be given for IP and ER
scores. The MDP can be completed in 2–3 min. The focal
period for the MDP is determined by users as appropriate
for the intent of the research or clinical situation (e.g.,
“right now” or “at the end of a minute of a particular
activity”). In this study, the time frame was “the past 2
weeks” and the situation was “while resting without doing
any physical activity” named as the MDP-Resting and “at
the end of climbing a flight of 2-floor stairs” named as
the MDP-Activity. The original MDP and its translations
including Turkish are distributed by the Mapi Research
Trust. For permission to use the Turkish version of the
MDP, please access the website of the Mapi Research Trust
(https://eprovide.mapi-trust.org).
Other dyspnea instruments included the mMRC
[21], VAS [22], and MBS [23]. The VAS and MBS were
administered in the same way as the MDP (i.e., “while
resting without doing any physical activity during the past
2 weeks” was asked in the VAS-Rest and MBS-Rest, and
“at the end of climbing a flight of 2-floor stairs during the
past 2 weeks” was asked in the VAS-Activity and MBSActivity).
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The HADS was used to assess anxiety and depression
[24]. The health-related quality of life was measured using
the NHP which includes 6 subdomains: energy level, pain,
emotional reactions, sleep, social isolation, and physical
abilities [25].
2.5. Statistical analysis
The statistical analysis was performed using IBM SPSS
software (Version 25.0, IBM Corp., Armonk, NY). The
patients’ demographic characteristics and assessment
results were described using descriptive statistics.
The Cronbach’s alpha coefficients were calculated
to assess the internal consistency. The Cronbach’s alpha
coefficients were interpreted as excellent, >0.80; adequate,
0.70–0.79; and inadequate, <0.70 [26]. The intraclass
correlation coefficient (ICC) values with 95% confidence
intervals (95% CI) were calculated to assess test-retest
reliability. The ICC values were reported as very low ≤0.25,
low = 0.26–0.49, moderate = 0.50–0.69, high = 0.70–0.89,
and very high ≥0.90 [27].
An exploratory principal components analysis using
varimax rotation, using baseline data to determine the
underlying factorial structure of the MDP was used to
verify the 2-factor structure as defined in the original
validation study [12].
To assess the construct validity, correlations were
calculated between the MDP and measures of body mass
index, pulmonary function test, other dyspnea assessments
(VAS, mMRC Scale, and MBS), anxiety, depression, and
health-related quality of life. We formulated 17 hypotheses
for each MDP domain (in total, 34 for MDP-Activity, and
34 for MDP-Resting) on the strength of the association of
the MDP and construct variables. According to previous
validation studies to investigate the divergent validity, we
expected negligible/nonsignificant or weak correlations
with body mass index (BMI) and pulmonary function
test results. To assess concurrent validity, we expected
that higher MDP-Activity scores were associated with
higher VAS and MBS activity scores. Similarly, higher
MDP-Resting scores were expected to be associated with
higher VAS and MBS resting scores. Moderate-to-strong
correlations were expected between MDP and anxiety,
depression, and health-related quality of life (for the
details, see online supplementary material). A correlation
coefficient of <0.1 was considered negligible; 0.10–0.30
was considered small, 0.30–0.50 moderate, 0.50–0.70
strong, and 0.70–0.90 very strong. The level of significance
was set as P < 0.05 in all analyses.
3. Results
In total, 186 patients were screened and 170 of them met
inclusion criteria and completed the baseline MDP, and 30
patients completed MDP again after 1 h, and 89 patients
completed the MDP again after 1 week. The mean age
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of the participants was 61 (SD = 14) years. There were
52 female (30.6%) and 118 male (69.4%) participants.
Diagnoses were chronic obstructive pulmonary disease
(COPD), (46.5%), asthma (22.9%), and miscellaneous
(30.6%) such as pneumonia, idiopathic pulmonary
fibrosis, etc. The demographics and clinical characteristics
of the participants are presented in Table 1.
Internal consistency of the MDP-Activity IP and ER
domains was excellent (Cronbach’s alpha coefficient =
0.92 and 0.93, respectively). Internal consistency of the
MDP-Resting IP and ER was excellent (Cronbach’s alpha
coefficient = 0.90 and 0.89, respectively).
Test-retest ICC values between recall ratings for the
approximate 1-h interval ranged from 0.80 to 0.99 for the
individual items of the 2 domains of MDP-Activity. Both
the MDP-Activity IP and ER had 0.99 of ICC after the 1-h
interval. Test-retest ICCs between recall ratings for the
approximate 1-week interval were lower ranging from 0.38
to 0.62 for the individual items the 2 domains of MDPActivity. The ICC values for the MDP-Activity IP and ER
after the 1-week interval were 0.80 and 0.77, respectively.
The ICC values of the MDP-Resting were lower. Individual
item ICC values of the 2 domains of the MDP-Resting
ranged from 0.57 to 0.99. The ICC values for both the
MDP-Resting IP and ER after the 1-h interval were 0.98.
The ICC values for the MDP-Resting IP and ER after the
1-week interval were 0.53 and 0.54, respectively. Table 2
presents detailed test-retest reliability results.
The exploratory factor analysis revealed 2 components
explaining 76% variance for MDP-Activity and 70%
variance for MDP-Resting (Table 2). The Kaiser–Meyer–
Olkin (KMO) Measure of Sampling Adequacy and
Bartlett’s Test of Sphericity (P < 0.001) results showed
that the respondent data for factor analysis was suitable
for MDP (KMO values were 0.898 for MDP-Activity and
0.903 for MDP-Resting).
All predetermined hypotheses were confirmed for
MDP-Activity IP and 16 of the 17 hypotheses (94%)
were confirmed for the ER domain. All predetermined
hypotheses were confirmed for the MDP-Resting IP and
this ratio was 82% for the MDP-Resting ER domain.
Overall, 64 of the 68 hypotheses (94%) were confirmed
(Table 3, Table 4, Table 5, and Table 6). The associations
were in the expected direction in that higher MDPActivity scores were associated with higher VAS and MBS
activity scores (Table 3, Table 4, and Table 7). Similarly,
higher MDP-Resting scores were associated with higher
VAS and MBS resting scores (Table 5, Table 6, and Table 7).
The MDP-Activity and Resting scores were significantly
correlated with anxiety, depression, and health-related
quality of life scores. As expected, negligible/nonsignificant
correlations with BMI were overserved. We also expected
nonsignificant or weak correlations with pulmonary
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Table 1. Demographic and clinical characteristics of the participants (n = 170).
Nonmissing
observations

Mean (SD)

Age (years)

170

61 (14)

Sex, n (%)

170

Female

52 (30.6)

Male

118 (69.4)

BMI, kg/m

170

Diagnosis, n (%)

170

2

27.3 (4.9)

COPD

79 (46.5)

Asthma

39 (22.9)

Miscellaneous (pneumonia, idiopathic pulmonary fibrosis, etc.)

52 (30.6)

FEV1/FVC % predicted

131

67.8 (13.7)

FEV1 % predicted

136

64.7 (22.9)

FVC % predicted

138

75.5 (19.9)

MDP-Activity, Immediate Perception

170

26.4 (17.6)

MDP-Activity, Emotional Response

170

13.4 (15.4)

MDP-Resting, Immediate Perception

170

6.3 (10.1)

MDP-Resting, Emotional Response

170

6.9 (10.8)

VAS – Resting, mm

170

12.0 (21.5)

VAS – Activity, mm

170

49.8 (34.2)

MBS – Resting

170

1.4 (2.0)

MBS – Activity

170

5.3 (2.8)

mMRC Scale

170

2.2 (1.2)

HADS – Anxiety

170

6.5 (5.3)

HADS – Depression

170

5.8 (4.6)

NHP – Energy level

170

40.5 (37.0)

NHP – Pain

170

22.4 (29.9)

NHP – Emotional reaction

170

21.9 (26.8)

NHP – Social isolation

170

17.1 (25.1)

NHP – Sleep

170

20.9 (23.1)

NHP – Physical abilities

170

25.5 (25.7)

BMI: body mass index; COPD: chronic obstructive pulmonary disease; MDP: Multidimensional Dyspnea
Profile; VAS: Visual Analogue Scale; MBS: Modified Borg Scale; mMRC: Modified Medical Research
Council; HADS: Anxiety and Depression Scale; NHP: Nottingham Health Profile.

function test results, and all hypotheses were confirmed.
Correlations between the MDP–Activity, and MDP–
Resting domains and the other variables are presented in
Table 7.
4. Discussion
The current study was conducted to translate and culturally
adapt the MDP into Turkish and evaluate its psychometric

properties in outpatients across a range of important
respiratory diseases. The Turkish version of the MDP
showed excellent internal consistency and good construct
validity. The test-retest reliability was excellent for 1 h.
However, it tends to decrease after 1 week, especially for
MDP-Resting. The explanatory factor analysis modeling
demonstrated that the Turkish version of the MDP has a
2-factor structure including IP and ER.
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Table 2. Factor loadings and test-retest reliability results of the MDP-Activity and MDP-Resting.
MDP-Activity

MDP-Resting

Baseline –
After 1-h
(n = 170–30)

Baseline –
After 1 week
(n = 170–89)

Baseline –
After 1-h
(n = 170–30)

Factors
loadings

ICC

95% CI

ICC 95% CI

1. Intensity

0.86

0.93

0.86–0.97 0.61 0.47–0.73 0.73

0.91 0.82–0.96

0.38 0.19–0.54

2. Muscle work/Effort

0.86

0.98

0.96–0.99 0.59 0.44–0.71 0.86

0.95 0.91–0.98

0.21 0.01–0.40

3. Not enough air/Smothering/
Air hunger

0.80

0.95

0.90–0.98 0.56 0.40–0.69 0.81

0.87 0.75–0.94

0.37 0.17–0.53

4. Tight/Constricted

0.83

0.85

0.70–0.92 0.52 0.36–0.66 0.76

0.98 0.95–0.99

0.21 0.01–0.40

5. Mental effort/Concentration

0.57

0.80

0.63–0.90 0.62 0.47–0.73 0.75

0.57 0.26–0.77

0.42 0.24–0.58

6. Breathing a lot
(rapid, deep, heavy)

0.86

0.89

0.77–0.94 0.58 0.42–0.70 0.72

0.99 0.99–0.99

0.12 -0.09–0.32

Immediate Perception Domain
(Mean of 6 items)

–

0.99

0.99–0.99 0.80 0.69–0.87 –

0.98 0.95–0.99

0.53 0.28–0.69

1. Depressed

0.87

0.98

0.97–0.99 0.50 0.32–0.64 0.83

0.96 0.92–0.98

0.21 0.01–0.39

2. Anxious

0.86

0.99

0.98–0.99 0.59 0.43–0.71 0.86

0.92 0.84–0.96

0.21 0.01–0.40

3. Frustrated

0.88

0.96

0.92–0.98 0.56 0.40–0.68 0.83

0.95 0.90–0.98

0.27 0.07–0.45

4. Angry

0.78

0.98

0.96–0.99 0.38 0.19–0.55 0.70

0.95 0.89–0.97

0.05 -0.15–0.26

5. Afraid

0.82

0.99

0.97–0.99 0.62 0.48–0.73 0.75

0.88 0.76–0.94

0.26 0.06–0.44

Emotional Response Domain
(Mean of 5 items)

–

0.99

0.99–0.99 0.77 0.65–0.85 –

0.98 0.95–0.99

0.54 0.27–0.70

Factors
ICC 95% CI
loadings

Baseline –
After 1 week
(n = 170–89)
ICC 95% CI

Immediate Perception items

Emotional Response items

MDP: Multidimensional Dyspnea Profile; ICC: Intraclass Correlation Coefficient; CI: Confidence Interval.

The 2 domains of the Turkish version of the MDP
showed excellent internal consistency for both Activity
and Resting situations. This result was similar to that
reported in previous studies. Internal consistency of these
2 domains was also moderate to very high in the Swedish
[16], Portuguese [15], and English [5,11] versions of the
MDP.
The Turkish version of the MDP showed excellent
test-retest reliability for 1 h. However, test-retest reliability
decreased moderate-to-high after 1 week. High test-retest
reliability results for a short interval (hours to days) have
been reported in the other validation studies [5,11,15,16].
Similar to our findings, test-retest reliability tends to
decrease after weeks [5,11,16]. However, it should be
noted that the decline is not dramatic, and the test-retest
reliability is still at least moderate.
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In this study, the MDP showed a 2-factor structure for
both determined situations (i.e., activity and rest) similar to
findings in the previous validation studies [5,11,15,16,18]. In
the original development study of the MDP, three domains
were proposed as an immediate sensory response, immediate
unpleasantness, and resultant emotional response under
sensory and affective dimensions based on a well-developed
conceptual model of pain perception [3]. In that model,
the “breathing discomfort” item should be in the affective
dimension. However, our study and other studies suggested
that the MDP has a 2-factor structure as IP and ER domains,
and “breathing discomfort” item is clustered under the IP
domain [5,11,12,15,16,18]. These results suggest that 2
domains are necessary to describe dyspnea.
In our study, most of the predetermined hypotheses
were confirmed showing construct validity. Although
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Table 3. Hypothesis testing to assess the construct validity of the MDP-Activity, Immediate Perception.
Hypothesis

Construct validity is confirmed when the
correlation is

Results

Interpretation of
results

1. Negligible/nonsignificant correlation with
BMI

Negligible/nonsignificant
(|rho| ≤ 0.1; P > 0.05)

0.02

Confirmed

2. Nonsignificant/weak correlation with
FEV1/FVC % predicted

Nonsignificant (P > 0.05) or Weak
(0.1 ≤ |rho| ≤ 0.3)

–0.03

Confirmed

3. Nonsignificant/weak correlation with
FEV1 % predicted

Nonsignificant (P > 0.05) or Weak
(0.1 ≤ |rho| ≤ 0.3)

–0.19

Confirmed

4. Nonsignificant/weak correlation with
FVC % predicted

Nonsignificant (P > 0.05) or Weak
(0.1 ≤ |rho| ≤ 0.3)

–0.24

Confirmed

5. Moderate correlation with VAS – Resting

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.48

Confirmed

6. Strong correlation with VAS – Activity

Strong (|rho| ≥ 0.5)

0.68

Confirmed

7. mMRC Scale

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.38

Confirmed

8. MBS – Resting

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.41

Confirmed

9. MBS – Activity

Strong (|rho| ≥ 0.5)

0.59

Confirmed

10. HADS – Anxiety

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.37

Confirmed

11. HADS – Depression

Weak (0.1 ≤ |rho| ≤ 0.3)

0.26

Confirmed

12. NHP – Energy level

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.43

Confirmed

13. NHP – Pain

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.44

Confirmed

14. NHP – Emotional reaction

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.37

Confirmed

15. NHP – Social isolation

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.37

Confirmed

16. NHP – Sleep

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.37

Confirmed

17. NHP – Physical abilities

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.51

Confirmed

Statistically significant correlations are shown in bold.
Confirmed hypotheses for the MDP-Activity, Immediate Perception = 17/17 (100%).
MDP: Multidimensional Dyspnea Profile; VAS: Visual Analogue Scale; mMRC: Modified Medical Research Council; HADS: Hospital
Anxiety and Depression Scale; BMI: body mass index; MBS: Modified Borg Scale; NHP: Nottingham Health Profile.

some outcome measures were different from ours
and some correlations were slightly different for the
same measures in the other validation studies, they
also reported that the MDP had construct validity
[5,11,15,16,18]. Since the FEV1 is weakly associated
with the severity of dyspnea [18], we expected to
find nonsignificant or weak correlations and it was
confirmed. Ekström et al. [16], Williams et al. [18], and
Meek et al. [5] also showed weak correlations between
the MDP domains and FEV1 results. In addition to the
FEV1, we also investigated the other commonly used
spirometry parameters (FEV1/FVC and FVC), and the
correlation results were quite similar as no significant
or weak correlations were observed. Meek et al. [5] also

reported no significant correlation between the MDP
domains and FVC, and Williams et al. [18] reported no
significant or weak correlations between the FEV1/FVC
and MDP domains. These results extend the evidence
that spirometry results were weakly associated with the
perception of dyspnea. To further support the divergent
validity of the MDP, we investigated the correlations with
BMI and found no significant correlation per Meek et
al. [5].
Based on the underlying concept of MDP, many
studies evaluated depression and anxiety levels to assess its
concurrent validity. Strong correlations between the MDP
domains and HADS-Anxiety and HADS-Depression were
observed in these studies [15,16,18] as in our results.
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Table 4. Hypothesis testing to assess the construct validity of the MDP-Activity, Emotional Response.
Hypothesis

Construct validity is confirmed when the
correlation is

Results

Interpretation of
results

1. BMI

Negligible/nonsignificant
(|rho| ≤ 0.1; P > 0.05)

0.13

Confirmed

2. FEV1/FVC % predicted

Nonsignificant (P > 0.05) or Weak
(0.1 ≤ |rho| ≤ 0.3)

0.09

Confirmed

3. FEV1 % predicted

Nonsignificant (P > 0.05) or Weak
(0.1 ≤ |rho| ≤ 0.3)

–0.09

Confirmed

4. FVC % predicted

Nonsignificant (P > 0.05) or Weak
(0.1 ≤ |rho| ≤ 0.3)

–0.18

Confirmed

5. VAS – Resting

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.36

Confirmed

6. VAS – Activity

Strong (|rho| ≥ 0.5)

0.59

Confirmed

7. mMRC Scale

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.30

Confirmed

8. MBS – Resting

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.35

Confirmed

9. MBS – Activity

Strong (|rho| ≥ 0.5)

0.39

Not confirmed

10. HADS – Anxiety

Moderate to strong (|rho| ≥ 0.3)

0.53

Confirmed

11. HADS – Depression

Moderate to strong (|rho| ≥ 0.3)

0.34

Confirmed

12. NHP – Energy level

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.42

Confirmed

13. NHP – Pain

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.44

Confirmed

14. NHP – Emotional reaction

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.50

Confirmed

15. NHP – Social isolation

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.42

Confirmed

16. NHP – Sleep

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.34

Confirmed

17. NHP – Physical abilities

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.50

Confirmed

Statistically significant correlations are shown in bold.
Confirmed hypotheses for the MDP-Activity, Emotional Response = 16/17 (94%).
MDP: Multidimensional Dyspnea Profile; VAS: Visual Analogue Scale; BMI: body mass index; MBS: Modified Borg Scale; mMRC:
Modified Medical Research Council; HADS: Hospital Anxiety and Depression Scale; NHP: Nottingham Health Profile.

Although Meek et al. [5] used different outcome measures
(Brief Symptom Inventory) to assess depression and
anxiety, they also showed strong correlations.
Many studies also used the mMRC scale, which assesses
functional impairment due to dyspnea to investigate the
validity of the MDP and reported moderate to strong
correlations [5,15,16]. We also observed moderate
correlations between the MDP domains and the mMRC
scale. To further support the concurrent validity, we also
used the MBS and VAS. Since we used the same periods
and situations while administrating the MBS and VAS,
their correlations were much stronger compared to the
mMRC scale. Williams et al. [18] and Banzett et al. [12]
also used the mMRC, VAS, and MBS, and similarly and
found similar results. Since the mMRC has embedded
questions whereas the VAS and MBS asked the same
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time frame and situations as the MDP, these results were
expected.
It is a well-known fact that dyspnea can be associated
with poor health-related quality of life [28]. Therefore,
we included a health-related quality of life measure as an
anchor to investigate the concurrent validity of MDP and
found moderate to strong correlations between the MDP
and subdomains of health-related quality of life measures.
Only the Swedish validation study of the MDP used a
quality of life measure and found similar results [16]. These
findings suggest that dyspnea is closely associated with
health-related quality of life, not only in a unidimensional
[28] but also in a multidimensional manner.
Since the MDP is not a disease-specific measure,
the MDP validation studies were conducted under
different conditions, and laboratory and clinical settings
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Table 5. Hypothesis testing to assess the construct validity of the MDP-Resting, Immediate Perception.
Hypothesis

Construct validity is confirmed when the
correlation is

Results

Interpretation of
results

1. BMI

Negligible/nonsignificant
(|rho| ≤ 0.1; P > 0.05)

0.01

Confirmed

2. FEV1/FVC % predicted

Nonsignificant (P > 0.05) or Weak
(0.1 ≤ |rho| ≤ 0.3)

0.19

Confirmed

3. FEV1 % predicted

Nonsignificant (P > 0.05) or Weak
(0.1 ≤ |rho| ≤ 0.3)

–0.03

Confirmed

4. FVC % predicted

Nonsignificant (P > 0.05) or Weak
(0.1 ≤ |rho| ≤ 0.3)

–0.06

Confirmed

5. VAS – Resting

Strong (|rho| ≥ 0.5)

0.75

Confirmed

6. VAS – Activity

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.48

Confirmed

7. mMRC Scale

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.31

Confirmed

8. MBS – Resting

Strong (|rho| ≥ 0.5)

0.60

Confirmed

9. MBS – Activity

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.36

Confirmed

10. HADS – Anxiety

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.39

Confirmed

11. HADS – Depression

Weak (0.1 ≤ |rho| ≤ 0.3)

0.25

Confirmed

12. NHP – Energy level

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.45

Confirmed

13. NHP – Pain

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.36

Confirmed

14. NHP – Emotional reaction

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.35

Confirmed

15. NHP – Social isolation

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.36

Confirmed

16. NHP – Sleep

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.32

Confirmed

17. NHP – Physical abilities

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.44

Confirmed

Statistically significant correlations are shown in bold.
Confirmed hypotheses for the MDP-Resting, Immediate Perception = 17/17 (100%).
MDP: Multidimensional Dyspnea Profile; VAS: Visual Analogue Scale; BMI: body mass index; MBS: Modified Borg Scale; mMRC:
Modified Medical Research Council; HADS: Hospital Anxiety and Depression Scale; NHP: Nottingham Health Profile.

included patients with dyspnea in the acute emergency
setting, patients with COPD, or outpatients with various
cardiorespiratory diseases [4,5,11,12,15,16,18,29,30]. We
also investigated the psychometric properties of the MDP
in a quite different population including outpatients with
different respiratory diseases, and found similar reliability
and validity results. These findings support that the MDP is
valid for measurement and comparison of dyspnea across
different populations and settings. Therefore, the Turkish
version of the MDP can be used without adaptations in
various conditions and settings.
Another advantage of the MDP is that the time frame
and situation can be specified by the user, depending on
the setting and aim [12]. The validation studies used many
different periods and situations including “during the last
2 weeks”, “during the last 15 days”, “right now”, “now”, “the
worst experience”, “during activities of daily living”, “on

average over the past 2 weeks”, “when you decided to come
to the emergency department”, and “during the last minute
of the walk test” [5,11,13,15,18]. In this study, we used
time frames and situations such as “while resting without
doing any physical activity during the past 2 weeks” and “at
the end of climbing a flight of 2-floor stairs during the past
2 weeks”. We intended to focus on a specific activity that
is known to trigger dyspnea, and a normal resting state.
Similar findings obtained from different studies suggest
that the psychometric properties of MDP are consistent
across different time frames and situations, even if the
actual intensity levels for items may vary.
Our study had some limitations. First, we did not
investigate other psychometric properties such as
responsiveness and interrater reliability. However, Meek et
al. [5] showed that the responsiveness to change in MDP
domains with treatment and Belo at al. [15] found that
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Table 6. Hypothesis testing to assess the construct validity of the MDP-Resting, Emotional Response.
Hypothesis

Construct validity is confirmed when the
correlation is

Results

Interpretation of
results

1. BMI

Negligible/nonsignificant
(|rho| ≤ 0.1; P > 0.05)

0.07

Confirmed

2. FEV1/FVC % predicted

Nonsignificant (P > 0.05) or Weak
(0.1 ≤ |rho| ≤ 0.3)

0.29

Confirmed

3. FEV1 % predicted

Nonsignificant (P > 0.05) or Weak
(0.1 ≤ |rho| ≤ 0.3)

0.03

Confirmed

4. FVC % predicted

Nonsignificant (P > 0.05) or Weak
(0.1 ≤ |rho| ≤ 0.3)

–0.12

Confirmed

5. VAS – Resting

Strong (|rho| ≥ 0.5)

0.59

Confirmed

6. VAS – Activity

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.45

Confirmed

7. mMRC Scale

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.29

Confirmed

8. MBS – Resting

Strong (|rho| ≥ 0.5)

0.43

Not confirmed

9. MBS – Activity

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.24

Not confirmed

10. HADS – Anxiety

Moderate to strong (|rho| ≥ 0.3)

0.35

Confirmed

11. HADS – Depression

Moderate to strong (|rho| ≥ 0.3)

0.15

Not confirmed

12. NHP – Energy level

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.39

Confirmed

13. NHP – Pain

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.39

Confirmed

14. NHP – Emotional reaction

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.35

Confirmed

15. NHP – Social isolation

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.36

Confirmed

16. NHP – Sleep

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.29

Confirmed

17. NHP – Physical abilities

Moderate (0.3 ≤ |rho| ≤ 0.5)

0.37

Confirmed

Statistically significant correlations are shown in bold.
Confirmed hypotheses for the MDP-Resting, Emotional Response = 14/17 (82%).
MDP: Multidimensional Dyspnea Profile; VAS: Visual Analogue Scale; BMI: body mass index; MBS: Modified Borg Scale; mMRC:
Modified Medical Research Council; HADS: Hospital Anxiety and Depression Scale; NHP: Nottingham Health Profile.

the MDP was reliable independently of different raters.
Second, we performed a principal component analysis
rather than a confirmatory factor analysis. However, both
methods generally agree on the number of components
and which items load primarily on which factors [31].
Supporting this, some MDP validation studies used
a principal component analysis and the others used a
confirmatory factor analysis or both, and their results
are consistent [5,11,12,15,16,18]. Another limitation is
the use of a convenience sample and the exclusion of the
patients who did not speak or understand Turkish, who
were unwilling to participate, and who had completed the
study measures.
Apart from the limitations noted above, our study
had several strengths. Our sample was large and included
outpatients with many different respiratory diseases,
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supporting the existing evidence that the MDP is not a
disease-specific instrument. Our study demonstrated for
the first time that the MDP is valid and reliable to assess
the dyspnea in a resting state without physical activity.
Apart from many previous validation studies of MDP,
we used a relatively broad range of outcome measures to
assess validity. Considering the high prevalence of Turkishspeaking populations not only in Turkey but also in Europe,
we believe that the Turkish version of the MDP will gain a
high utilization rate. The MDP has been validation in many
languages and many other language validations studies are
ongoing that show its international acceptance. The Turkish
version of the MDP will allow conducting multicultural
and multicentered international studies.
In conclusion, the MDP was successfully translated and
culturally adapted into Turkish, and this version showed good

ÖZCAN KAHRAMAN et al. / Turk J Med Sci
Table 7. Correlations between the MDP–Activity and MDP–Resting subscales and validation variables.

BMI, kg/m
FEV1/FVC % predicted (n = 131)
FEV1 % predicted (n = 136)
FVC % predicted (n = 138)
VAS – Resting, mm
VAS – Activity, mm
MBS – Resting
MBS – Activity
mMRC Scale
HADS – Anxiety
HADS – Depression
NHP – Energy level
NHP – Pain
NHP – Emotional reaction
NHP – Social isolation
NHP – Sleep
NHP – Physical abilities
2

MDP–Activity

MDP–Resting

Immediate Perception Emotional Response

Immediate Perception Emotional Response

0.02
–0.03
–0.19
–0.24
0.48
0.68
0.41
0.59
0.38
0.37
0.26
0.43
0.44
0.37
0.37
0.37
0.51

0.01
0.19
–0.03
–0.06
0.75
0.48
0.60
0.36
0.31
0.39
0.25
0.45
0.36
0.35
0.36
0.32
0.44

0.13
0.09
–0.09
–0.18
0.36
0.59
0.35
0.39
0.30
0.53
0.34
0.42
0.44
0.50
0.42
0.34
0.50

0.07
0.29
0.03
–0.12
0.59
0.45
0.43
0.24
0.29
0.35
0.15
0.39
0.39
0.35
0.36
0.29
0.37

Statistically significant correlations are shown in bold.
BMI: body mass index; MDP: Multidimensional Dyspnea Profile; VAS: Visual Analogue Scale; MBS: Modified Borg Scale; mMRC:
Modified Medical Research Council; HADS: Hospital Anxiety and Depression Scale; NHP: Nottingham Health Profile.

psychometric properties including the factorial structure,
internal consistency, test-retest reliability, and construct
validity to assess multidimensional aspects of dyspnea.
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